Masimo has secured approval from the US Food and Drug Administration (FDA) for its SedLine brain function monitoring system.
The new SedLine system features an advanced signal processing engine, providing clinicians with a complete picture of the brain.
Masimo’s next generation system is said to offer an enhanced patient state index (PSi) based on signal processing engine. A PSi is a processed EEG parameter linked to the effect of anesthetic agents.
The system also includes an advanced multitaper density spectral array (DSA), which is developed by Dr. Emery Brown and Dr. Patrick Purdon of the Neuroscience Statistics Research Lab at Massachusetts General Hospital.
The EEG data will be translated into the frequency domain when showing a Multitaper DSA, enabling to offer a better picture of EEG features.
Masimo’s new SedLine, along with the RD SedLine EEG sensor, can be simultaneously used with O3 regional oximetry on the Root patient monitoring and connectivity platform for better insight into a patient's brain.
The O3 system helps clinicians to monitor cerebral oxygenation in condition in which pulse oximetry alone may not be fully indicative of the oxygen in the brain.
Masimo founder and CEO Joe Kiani said: "Masimo is committed to innovation in the brain function monitoring space.
“With the improved performance offered by its enhanced signal processing capabilities, we expect Next Generation SedLine to impact brain function monitoring just as SET impacted pulse oximetry."
Masimo, which provides noninvasive monitoring technologies, launched Masimo SET measure-through motion and low perfusion pulse oximetry in 1995.
Image: Masimo Root with next generation SedLine brain function monitoring system. Photo: courtesy of Masimo.